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Abstract
Stroke recovery is the next frontier in stroke medicine. While growth in rehabilitation and recovery research is exponential, 
a number of barriers hamper our ability to rapidly progress the field. Standardized terminology is absent in both animal and 
human research, methods are poorly described, recovery biomarkers are not well defined, and we lack consistent timeframes 
or measures to examine outcomes. Agreed methods and conventions for developing, monitoring, evaluating and reporting 
interventions directed at improving recovery are lacking, and current approaches are often not underpinned by biology. We 
urgently need to better understand the biology of recovery and its time course in both animals and humans to translate 
evidence from basic science into clinical trials. A new international partnership of stroke recovery and rehabilitation experts 
has committed to advancing the research agenda. In May 2016, the first Stroke Recovery and Rehabilitation Roundtable will 
be held, with the aim of achieving an agreed approach to the development, conduct and reporting of research. A range of 
methods will be used to achieve consensus in four priority areas: pre-clinical recovery research; biomarkers of recovery; 
intervention development, monitoring and reporting; and measurement in clinical trials. We hope to foster a global network 
of researchers committed to advancing this exciting field. Recovery from stroke is challenging for many survivors. They 
deserve effective treatments underpinned by our evolving understanding of brain recovery and human behaviour. Working 
together, we can develop game-changing interventions to improve recovery and quality of life in those living with stroke.
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Introduction: The Problem and 
Solution
The explosion of knowledge about the stroke-damaged 
brain must be incorporated into our collective thinking 
about the nature and delivery of rehabilitation and restor-
ative therapies.1 Variable methodological quality of animal 
studies,2 poorly defined interventions,3 and lack of agreed 
methods for developing, monitoring, evaluating and report-
ing interventions limit translation of research into evidence-
based therapies.4 Furthermore, patient descriptions are not 
standardized, recovery biomarkers are not well defined,5 
and we lack agreed time-points or measures to examine out-
comes in rehabilitation and recovery trials.6
By creating an international partnership of experts from 
a broad range of scientific and clinical disciplines, we aim 
to achieve consensus on developing, conducting and report-
ing rehabilitation and recovery research, and create a new 
community of practice. In this first roundtable, four areas 
that we will examine represent important roadblocks to cur-
rent research efforts. The aim of this paper is to summarize 
priorities for each theme.
Theme 1: Pre-Clinical Recovery 
Research: “Addressing the First 
Translational Gap”
To address the first gap in translation, we need to better 
translate pre-clinical evidence into human discovery trials 
in a bidirectional and iterative manner. The goal is to 
develop a deeper understanding of the neurobiology of 
recovery in human stroke survivors. Basic scientists need 
to understand the most pressing issues in stroke recovery 
and rehabilitation and work closely with their clinical 
counterparts in designing studies, taking a "Bedside to 
Bench" approach instead of the conventional "Bench to 
Bedside" approach. Understanding the biology and timing 
of recovery in animals and in humans requires knowledge 
of underlying molecular mechanisms that may be influ-
enced by different therapies, such as rehabilitation and 
stem cells,5 with the potential to augment post-stroke plas-
ticity and brain repair. Methods for enhancing the potential 
for functional and structural plasticity in surviving brain 
and spinal cord are needed.7–9 Translation will improve by 
defining inter-species differences, developing robust, pre-
clinical animal models that better represent clinical stroke 
populations (older, with co-morbidities)10 who do not 
recover within a few weeks post-stroke,11 and identifying 
more reliable, valid, and sensitive histological and behav-
ioural outcomes.7 Another important issue is to hold pre-
clinical studies to the same quality standards and rigor as 
clinical research.12 Sample size, age groups, and gender 
differences are not often considered in pre-clinical studies, 
ultimately limiting their clinical translation.2,13,14 Thus, a 
main point of pre-clinical studies of stroke repair is to 
model human recovery.
Theme 2: Recovery Biomarkers
A key impediment to the development of new therapies for 
promoting recovery after stroke is not knowing who or 
when best to treat. One of the most important findings to 
emerge from decades of work in rodents was the identifica-
tion of a period of spontaneous biological recovery during 
which the effect of training is heightened.15 Investigating 
the mechanisms involved in humans would reveal exciting 
therapeutic targets. A different type of problem, specific to 
human studies, is heterogeneity in the residual structural 
and functional post-stroke brain architecture and the impact 
this has on potential interventions.16,17 The answer to “who 
and when” is the development of biomarkers to provide 
knowledge of both therapeutic targets and prognosis in 
human stroke. There are limited validated biological mark-
ers of stroke recovery, but promising potential targets exist.5 
We define stroke recovery biomarkers as “indicators of dis-
ease state that can be used clinically to reflect underlying 
molecular/cellular events and/or predict outcome associ-
ated with recovery from stroke,” which may include mark-
ers of biology (blood, genetics), imaging (structural, 
functional, chemical), neurophysiology (patterns of brain 
excitability or electrical activity), or combinations of 
such.1,18,19 While most research has explored relationships 
between late biomarkers3–6 months post-stroke) and final 
stages of recovery,19,20 investigation of early biomarkers 
(<7 days) reflecting the mechanisms of spontaneous bio-
logical recovery is an urgent priority. Furthermore, distinc-
tion is required between cross-sectional measures that 
capture biological state, measures that predict future clini-
cal events, and measures that change in parallel with behav-
ioural change; each of these has value in stroke research.
Blood biomarker analysis is viable because many brain-
derived molecules cross the blood–brain barrier, including 
micro-RNAs, lipids, short peptide chains, and exosomes. 
Based on similar analyses from traumatic brain injury21 and 
Alzheimer’s disease,22 there is an expectation of identifying 
molecular signatures of recovery post-stroke in humans.23 
Individuals’ genetic profiles may also influence recovery.24–26 
While interest has centred on genes known to contribute to 
neuroplasticity,27 there are a number of candidate biomarkers 
to consider as well as gene–gene interactions and epigenetics.
Considerable attention has focused on brain imaging to 
define post-stroke patterns of recovery. Imaging is non-
invasive and easily accessible, enabling categorization of 
brain anatomy, function, chemistry, and connectivity.28–31 
Another potential recovery biomarker is neurophysiologi-
cal status mapped using non-invasive brain stimulation (i.e. 
transcranial magnetic stimulation (TMS)).19,30 TMS-based 
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neurophysiological measures of the electrophysiological 
relationship(s) between the cortical hemispheres32 and cor-
ticospinal tract integrity via the generation of motor evoked 
potentials relate to motor outcome in chronic19,33 and acute 
stroke.34 However, their value in predicting recovery is not 
well understood.
Recovery biomarker use may foster developments in 
new therapies and improve clinical trial efficiency through 
better patient selection or stratification. Tailoring of thera-
pies for individual patients based on their capacity for neu-
ral reorganization and recovery will facilitate personalized 
interventions, guiding the delivery of effective treatment to 
the right people, at the right time. Once identified, we must 
define the psychometric qualities and performance of pro-
posed biomarkers at different time-points of recovery. 
Prediction models for patient subgroups would need to be 
validated; this would require large cohorts and the develop-
ment of a worldwide network.35
Theme 3: Intervention Development, 
Monitoring and Reporting
Sequential development, testing, and refining of interven-
tions through trial phasing are less common in stroke reha-
bilitation than other areas of stroke medicine. Furthermore, 
the description of interventions in stroke rehabilitation stud-
ies is typically incomplete and monitoring of interventions 
poorly described and reported,36 leading to significant 
research waste.3
The need for systematic development of complex inter-
ventions has been highlighted for some time and useful 
frameworks exist.37 To date, researchers employ various 
methods to develop interventions intended for evaluation, 
and many fail to describe the underpinning theoretical 
framework or intended biological mechanisms to improve 
recovery or outcomes. Dosing studies in the trial develop-
ment phase are rare38 and insufficient attention has been 
paid to how much training is needed, and when it should be 
applied to drive neurological recovery. Too often, our 
choice of intervention type, dose, or scheduling is arbi-
trarily assigned (as reflected in many meta-analyses of 
stroke rehabilitation interventions), with a “more is better” 
mantra that is likely too simplistic and may even be harmful 
at certain points in the recovery pathway.39 In complex 
behaviour change research, we see increased attention on 
co-design of interventions with the health consumer40; turn-
ing these types of interventions into standardized protocols 
for delivery in trials is not simple.
Intervention fidelity is also poorly addressed in most 
rehabilitation trials, with few reporting the methods used to 
monitor the delivery of interventions. While interest in the 
area is growing,41–43 establishing agreed standards for mon-
itoring and reporting of fidelity would significantly improve 
our research. When evidence of intervention efficacy exists, 
insufficient reporting of intervention protocol is a substan-
tial barrier to reliable implementation or replication of 
research findings; yet this has received little attention.3 The 
Template for Intervention Description and Replication, 
which provides authors with guidance about how to struc-
ture accounts of their interventions,44 is a step in the right 
direction. But we must improve how we develop, monitor 
and report interventions. This will reduce research waste 
and, when interventions are effective, hasten translation 
into clinical practice.
Theme 4: Measurement in Clinical 
Trials
The number of rehabilitation trials is growing exponen-
tially; however, many (98% of physical therapy trials in one 
recent review)45 are underpowered, single site, testing feasi-
bility of an intervention or are proof-of-concept trials. 
Systematic reviews of rehabilitation trials are challenging 
given the high variability in outcomes used, the timing of 
intervention delivery, and outcome assessment.6 These 
problems are further compounded by poor reporting of 
interventions raised in Theme 3. If researchers used a core 
set of trial measures, gathered at agreed time-points after 
stroke, our ability to compare results across trials, pool data 
for meta-analyses or undertake individual patient meta-
analyses would be vastly improved. Large pooled data sets 
from rehabilitation trials could be used to develop hypoth-
eses about stroke recovery or help validate prognostic tools. 
We also need to consider how we stratify patients in trials 
and whether recovery biomarkers are robust enough for that 
purpose (Theme 2). When recruitment occurs later after 
stroke, some measure of stroke severity at time of onset is 
critical to developing our understanding of recovery. We 
may need to consider new recruitment models that track 
patients from stroke onset or retrospectively acquiring reli-
able and simple proxy measures of baseline severity. 
Insufficient attention has also been paid to systematic 
acquisition of pre-stroke lifestyle and other variables that 
are likely to inform stroke recovery phenotypes.
Limitations of many measurement tools are well 
known, and a number of frameworks exist to support 
selection of core measurements, for example the interna-
tional classification of functioning, disability and health 
model, and COSMIN (www.cosmin.nl) which provides 
criteria for evaluating psychometric properties of tools. 
Importantly, we need to ensure that tools we adopt can 
measure meaningful change and can distinguish true neu-
rological repair from use of adaptation strategies to 
achieve a goal.46 Important achievements would be to 
standardize definitions for common terms (e.g. recovery), 
time-points of measurement, and distinguish between 
different types of outcomes.47 Simply stated, our challenge 
is not just to agree a core set of measurements but to 
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consider what we need to measure and why, to improve 
rehabilitation and recovery trial methods.48,49
Conclusion
A new partnership of around 60 leading stroke experts has 
committed to advancing stroke recovery and rehabilitation, 
by achieving an agreed approach on how to develop, con-
duct, and report research across the four reported themes. A 
key issue to address is defining important time-points in 
stroke recovery, underpinned by our best understanding of 
biological processes. The next step towards developing con-
sensus is the inaugural Stroke Recovery and Rehabilitation 
Roundtable meeting, to be held in Philadelphia, USA, in 
May 2016. Recommendations from this meeting will be piv-
otal for progressing stroke recovery and rehabilitation 
research, and provide impetus for development of strong 
international partnerships to tackle the challenge of improv-
ing stroke recovery.
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